An update on diagnosing and treating canine lymphosarcoma

Veterinary Medicine

Volumn 97, Issue 1, 2002, Pages

  Fan, Timothy M ^a   Kitchell, Barbara E ^a  

^a Veterinary Teaching Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; CYCLOPHOSPHAMIDE; DOXORUBICIN; IMMUNOTOXIN; MONOCLONAL ANTIBODY; PREDNISOLONE; VINCRISTINE SULFATE;

CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; DRUG MEGADOSE; LYMPHOCYTE; LYMPHOSARCOMA; NONHUMAN; RADIOTHERAPY; REVIEW;

EID: 0036110124     PISSN: 87507943     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. Rosenthal, R.C.: The treatment of multicentric canine lymphoma. Vet. Clin. North Am. (Small Anim. Pract.) 20 (4):1093-1104; 1990.
2. Hayes, H.M. et al.: Case-control study of canine malignant lymphoma: Positive association with dog owner's use of 2,4-dichlorophenoxyacetic acid herbicides. J. Natl. Cancer Inst. 83 (17):1226-1231; 1991.
3. Reif, J.S. et al.: Residential exposure to magnetic fields and risk of canine lymphoma. Am. J. Epidemiol. 141 (4):352-359; 1995.
4. Chapman, A.L. et al.: Preliminary report on virus-like particles in canine leukemia and derived cell cultures. Cancer Res. 27 (1):18-25; 1967.
5. Madewell, B.R.; Theilen, G.H.: Hematopoietic neoplasms, sarcomas and related conditions: Canine. Part IV. Veterinary Cancer Medicine, 2nd Ed. (G.H. Theilen; B.R. Madewell, eds.). Lea & Febiger, Philadelphia, Pa., 1987; pp 392-407.
6. Couto, C.G.: Canine lymphomas: Something old, something new. Compend. Cont. Ed. 7 (4):291-296; 1985.
7. Couto, C.G. et al.: Gastrointestinal lymphoma in 20 dogs: A retrospective study. J. Vet. Intern. Med. 3 (2):73-78; 1989.
8. Blackwood, L. et al.: Radiographic abnormalities in canine multicentric lymphoma: A review of 84 cases. J. Small Anim. Pract. 38 (2):62-69; 1997.
9. Teske, E.: Canine malignant lymphoma: A review and comparison with human non-Hodgkin's lymphoma. Vet. Quart. 16 (4):209-219; 1994.
10. Meuten, D.J. et al.: Hypercalcemia in dogs with lymphosarcoma. Biochemical, ultrastructural, and histomorphometric investigations. Lab. Invest. 49 (5):553-562; 1983.
11. Weir, E.C. et al.: Humoral hypercalcemia of malignancy in canine lymphosarcoma. Endocrinology 122 (2):602-608; 1988.
12. Beale, K.M.; Bolon, B.: Canine cutaneous lymphosarcoma: Epitheliotropic and non-epitheliotropic, a retrospective study. Advances in Veterinary Dermatology, Vol. 2 (P.J. Ihrke et al., eds.). Pergamon Press, Oxford, England, 1992; pp 273-284.
13. Carter, R.F. et al.: The cytology, histology and prevalence of cell types in canine lymphoma classified according to the National Cancer Institute Working Formulation. Can. J. Vet. Res. 50 (2):154-164; 1986.
14. Teske, E. et al.: Prognostic factors for treatment of malignant lymphoma in dogs. JAVMA 205(12):1722-1728; 1994.
15. Milner, R.J. et al.: Immunophenotypic classification of canine malignant lymphoma on formalin-fixed paraffin wax-embedded tissue by means of CD3 and CD79a cell markers. Onderstepoort J. Vet. Res. 63 (4):309-313; 1996.
16. Burnett, R.C.; Avery, A.C.: Molecular aspects of canine lymphoma: PCR for antigen receptor rearrangements (PARR). Proc. 19th Ann. Vet. Med. Forum, 2001; pp 447-448.
17. Teske, E. et al.: DNA ploidy and cell kinetic characteristics in canine non-Hodgkin's lymphoma. Exp. Hematol. 21 (4):579-584; 1993.
18. Starrak, G.S. et al.: Correlation between thoracic radiographic changes and remission/ survival duration in 270 dogs with lymphosarcoma. Vet. Radiol. Ultrasound 38 (6):411-418; 1997.
19. Yohn, S.E. et al.: Confirmation of a pulmonary component of multicentric lymphosarcoma with bronchoalveolar lavage in two dogs. JAVMA 204 (1):97-101; 1994.
20. Couto, C.G. et al.: Central nervous system lymphosarcoma in the dog. JAVMA 184 (7):809-813; 1984.
21. Keller, E.T. et al.: Evaluation of prognostic factors and sequential combination chemotherapy with doxorubicin for canine lymphoma. J. Vet. Intern. Med. 7 (5):289-295; 1993.
22. Ruslander, D.A. et al.: Immunophenotypic characterization of canine lymphoproliferative disorders. In Vivo 11 (2):169-172; 1997.
23. MacEwen, G.E.; Young, K.M.: Canine lymphoma and lymphoid leukemias. Small Animal Clinical Oncology, 2nd Ed. (S. Withrow; G.E. MacEwen, eds.). W.B. Saunders, Philadelphia, Pa., 1996; pp 451-471.
24. Liotta, L.A. et al.: Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation. Cell 64 (2):327-336; 1991.
25. Johansson, N. et al.: Matrix metalloproteinases in tumor invasion. Cell. Mol. Life Sci. 57 (1):5-15; 2000.
26. Hong, S.D. et al.: Expression of matrix metalloproteinase-2 and -9 in oral squamous cell carcinomas with regard to the metastatic potential. Oral Oncol. 36 (2):207-213; 2000.
27. Hanemaaijer, R. et al.: Increased gelatinase-A and gelatinase-B activities in malignant vs. benign breast tumors. Int. J. Cancer 86 (2):204-207; 2000.
28. Sehgal, G. et al.: Requirement for matrix metalloproteinase-9 (gelatinase B) expression in metastasis by murine prostate carcinoma. Am. J. Pathol. 152 (2):591-596; 1998.
29. Lana, S.E. et al.: Identification of matrix metalloproteinases in canine neoplastic tissue. AJVR 61 (2):111-114; 2000.
30. Lana, S.E. et al.: Matrix metalloproteinase levels as a predicator of early treatment failure in dogs with lymphoma. Proc. 19th Annual Veterinary Cancer Society Conference., Wood's Hole, Mass., 1999; p 47.
31. Roninson, I.B.: Molecular mechanism of multidrug resistance in tumor cells. Clin. Physiol. Biochem. 5 (3-4):140-151; 1987.
32. Bergman, P.J. et al.: Monoclonal antibody C219 immunohistochemistry against P-glycoprotein: Sequential analysis and predictive ability in dogs with lymphoma. J. Vet. Intern. Med. 10 (6):354-359; 1996.
33. MacEwen, E.G. et al.: Diagnosis and treatment of canine hematopoietic neoplasms. Vet. Clin. North Am. 7 (1):105-118; 1977.
34. Carter, R.F. et al.: Chemotherapy of canine lymphosarcoma with histopathological correlation: Doxorubicin alone compared to COP as first treatment regimen. JAAHA 23:587-596; 1987.
35. Postorino, N.C. et al.: Single agent therapy with Adriamycin for canine lymphosarcoma. JAAHA 25:221-225; 1989.
36. Squire, R.A. et al.: Clinical and pathologic study of canine lymphoma: Clinical staging, cell classification, and therapy. J. Natl. Cancer Inst. 51 (2):565-574; 1973.
37. Hardy, W.D. Jr.; Old, L.J.: L-asparaginase in the treatment of neoplastic diseases of the dog, cat and cow. Recent Results Cancer Res. 33:131-139; 1970.
38. Rosenthal, R.C.: Lymphosarcoma in dogs: Chemotherapy. Controversies in clinical oncology. Vet. Clin. North Am. (Small Anim. Pract.) 26 (1):63-71; 1996.
39. Moore, A.S. et al.: Actinomycin D for reinduction remission in dogs with resistant lymphoma. J. Vet. Intern. Med. 8 (5):343-344; 1994.
40. Van Vechten, M. et al.: Treatment of relapsed canine lymphoma with doxorubicin and dacarbazine. J. Vet. Intern. Med. 4 (4):187-191; 1990.
41. Rosenberg, M.P.; Matus, R.E.: The use of MOPP as rescue treatment for dogs with lymphoma. Proc. 11th Annual Veterinary Cancer Society Conference, 1991.
42. Moore, A.S. et al.: Lomustine (CCNU) for the treatment of resistant lymphoma in dogs. J. Vet. Intern. Med. 13 (5):395-398; 1999.
43. MacEwen, E.G. et al.: Cyclic combination chemotherapy of canine lymphosarcoma. JAVMA 178 (11):1178-1181; 1981.
44. Stone, M.S. et al.: Comparison of two protocols for induction of remission in dogs with lymphoma. JAAHA 27:315-321; 1991.
45. Khanna, C. et al.: Randomized controlled trial of doxorubicin versus dactinomycin in a multi-agent protocol for treatment of dogs with malignant lymphoma. JAVMA 213 (7):985-990; 1998.
46. Boyce, K.L.; Kitchell, B.E.: Treatment of canine lymphoma with COPLA/LVP. JAAHA 36 (5):395-403; 2000.
47. Chun, R. et al.: Evaluation of a high-dose chemotherapy protocol with no maintenance therapy for dogs with lymphoma. J. Vet. Intern. Med. 14 (2):120-124; 2000.
48. Deeg, H.J. et al.: Autologous marrow transplantation as consolidation therapy for canine lymphoma: Efficacy and toxicity of various regimens of total body irradiation. AJVR 46 (9):2016-2018; 1985.
49. Weiden, P.L. et al.: Total body irradiation and autologous marrow transplantation consolidation therapy for spontaneous canine lymphoma in remission. Exp. Hematol. 7 (suppl. 5):160-163; 1979.
50. Abrams-Ogg, A.C.G. et al.: Half-body radiation therapy versus maintenance chemotherapy for the treatment of dogs with multicentric lymphoma in remission. Proc. 19th Annual Veterinary Cancer Society Conference, Wood's Hole, Mass., 1999; p 8.
51. Helfand, S.C. et al.: The interleukin-2 receptor as a potential target in canine lymphoid malignancy. Proc. 19th Annual Veterinary Cancer Society Conference., Wood's Hole, Mass., 1999; p 56.
52. Olsen, E. et al.: Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J. Clin. Oncol. 19 (2):376-388; 2001.
53. Maloney, D.G.: Advances in immunotherapy of hematologic malignancies. Curr. Opin. Hematol. 5 (4):237-243; 1998.
54. Hainsworth, J.D.: Monoclonal antibody therapy in lymphoid malignancies. Oncologist 5 (5):376-384; 2000.
55. Kaminski M.S. et al.: Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody. N. Engl. J. Med. 329 (7):459-465; 1993.
56. Kaminski, M.S. et al.: Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J. Clin. Oncol. 14 (7):1974-1981; 1996.
57. + B-cell non-Hodgkin's lymphoma. J. Clin. Oncol. 17 (12):3793-3803; 1999.